• Arcus Biosciences set an in-person investor event for Oct. 20, 2026, to disclose new ARC-20 study data for casdatifan in kidney cancer.
• Results have not yet been presented; the update will cover performance across first-line combinations, a second-line combination, and late-line monotherapy.
• Management will frame whether casdatifan can serve as a backbone therapy across treatment lines, a key determinant of commercial positioning.
• Safety readouts are expected to support a first-line registrational trial planned for the fourth quarter of 2026.
• Updated evidence from a second-line regimen will align with a separate registrational study targeted to finish enrollment by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609220830BIZWIRE_USPR_____20260922_BW009299) on September 22, 2026, and is solely responsible for the information contained therein.